New alert via PocketInfo for CTIC:
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
Press Releases: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-news&nyo=0
SEC Filings: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-sec
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8
No comments:
Post a Comment